Ixico (LON:IXI) issued its earnings results on Monday. The company reported GBX (5.70) (($0.08)) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of GBX (4.90) (($0.07)) by GBX (0.80) (($0.01)), Bloomberg Earnings reports. Ixico had a negative return on equity of 35.21% and a negative net margin of 33.90%. The business had revenue of £411 million during the quarter.

Shares of Ixico (LON:IXI) opened at GBX 28.50 ($0.38) on Tuesday. Ixico has a twelve month low of GBX 22.20 ($0.30) and a twelve month high of GBX 40.05 ($0.54).

COPYRIGHT VIOLATION NOTICE: This piece was first reported by Watch List News and is the sole property of of Watch List News. If you are viewing this piece on another site, it was illegally stolen and reposted in violation of U.S. & international trademark & copyright laws. The legal version of this piece can be viewed at https://www.watchlistnews.com/ixico-ixi-announces-earnings-results/1758905.html.

About Ixico

IXICO plc is a brain health company. The Company’s brain health focus includes Alzheimer’s disease, Huntington’s disease, Parkinson’s disease, behavioral health and adolescent mental health. It is a provider of clinical trials services to pharmaceutical companies. Its products include Assessa, mehealth, MyBrainBook and TrialTracker.

Receive News & Ratings for Ixico Plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ixico Plc and related companies with MarketBeat.com's FREE daily email newsletter.